Company Introduction

Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With strong R&D capacity, Junshi Biosciences is at the cutting-edge of medical innovation. Our mission is to” Provide patients with world-class, trustworthy, affordable, and innovative drugs”.

We have established a globally integrated R&D process. With four R&D centers worldwide, we have the outstanding ability to discover and develop innovative biologics. Our strategic goal is “In China, For Global”.

The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Four of the company’s innovations have already reached the Chinese or international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody, approved in over 30 countries and regions including China, the US, the European Union, etc. Additionally, more than 30 drugs are currently in clinical development. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI®, and other novel therapies for the prevention and treatment of COVID-19.

We have two monoclonal antibody production bases in China with a combined fermentation capacity of 46,500L, undertaking the manufacturing of both investigational and commercial products.